Mazindol treatment of negative symptoms.
Neuropsychopharmacology
; 23(4): 365-74, 2000 Oct.
Article
en En
| MEDLINE
| ID: mdl-10989263
Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Escalas de Valoración Psiquiátrica
/
Trastornos Psicóticos
/
Esquizofrenia
/
Inhibidores de Captación de Dopamina
/
Mazindol
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neuropsychopharmacology
Asunto de la revista:
NEUROLOGIA
/
PSICOFARMACOLOGIA
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido